Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland

Research output: Contribution to journalJournal articleResearchpeer-review

Andreas Klaus Pfeifer, Tine Gregersen, Henning Grønbæk, Carsten Palnæs Hansen, Jan Müller-Brand, Karin Herskind Bruun, Klaus Krogh, Andreas Kjær, Ulrich Knigge

Limited therapeutic options have highlighted the demand for new treatment modalities for patients with advanced neuroendocrine tumors (NET). Promising results of initial studies have warranted the implementation of peptide receptor radionuclide therapy (PRRT) in clinical practice. However, this treatment option still needs clinical evaluation.
Original languageEnglish
Issue number3
Pages (from-to)189-96
Number of pages8
Publication statusPublished - 2011

ID: 40171591